$CKPT Checkpoint $3.50 target

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.